PFIZER · Health Care · 2026-08-21

Pfizer Ltd

Stage 1 · wk 2In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹4,978.2
+1.18% today
₹22,774 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
29.3
Forward 22.8
Earnings Growth (YoY)
-39.6%
Revenue +6.3%
ROE
+17.2%
Profit margin +28.7%
Dividend Yield
1.62%
P/B 5.5
vs 52W High
-13.7%
₹4,404.9 lo₹5,766.5 hi
13.7% below 52W high — pullback range
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 2
1w13w26w
Week 2 — early base, needs time
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
3.6%
200 DMA: ₹4,806.8 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.55x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↗
MA20 gently rising · +2.8% vs MA50 +2.1%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S1 17w
S2 29w
S2 21w
S4 16w
S4 14w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 17w → S2 29w → S3 7w → S2 21w → S3 12w → S4 16w → S1 5w → S2 9w → S3 9w → S2 2w → S3 8w → S4 14w → S1 3w → S4 13w → S1 1w current
Total tracked: 168 weeks across 15 stage runs.
1M
+7.0%
3M
+6.6%
6M
-0.8%
YTD
+0.4%
1Y
-2.5%
Scan Membership
Breakout Watch
Latest: 2025-10-28
3 appearances in last 60 days. First seen: 2024-06-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S1
Wk 2 · Vol —x
2026-08-20S1
Wk 2 · Vol —x
2026-08-19S1
Wk 2 · Vol —x
2026-08-18S1
Wk 1 · Vol —x
2026-08-17S1
Wk 1 · Vol —x
2026-08-14S1
Wk 1 · Vol —x
2026-08-13S1
Wk 1 · Vol —x
2026-08-12S14→1
Wk 1 · Vol —x
2026-08-11S4
Wk 13 · Vol —x
2026-08-10S4
Wk 13 · Vol —x
2026-08-07S4
Wk 13 · Vol —x
2026-08-06S4
Wk 12 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹4,682.7
200 DMA
₹4,806.8
52W High
₹5,766.5
52W Low
₹4,404.9
5D Low
₹4,799.3
Resistance levels (recent highs)
20d High
₹5,017.6
60d High
₹5,017.6
120d High
₹5,146.2
250d High
₹5,698.5
Next resistance
+0.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.